The Role of Probiotics in the Prevention and Treatment of Antibiotic-Associated Diarrhea and Clostridium Difficile Colitis

Gastroenterology Clinics of North America

Volumn 41, Issue 4, 2012, Pages 763-779

  Friedman, Gerald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic; Diarrhea; Leukocytosis; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BACITRACIN; BACTERIAL VACCINE; BACTERIOCIN; CLAVULANIC ACID; CLOSTRIDIUM DIFFICILE TOXOID VACCINE; ERYTHROMYCIN; FIDAXOMICIN; FUSIDIC ACID; GUAIAC; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; METRONIDAZOLE; MUCIN; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TOLEVAMER; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VANCOMYCIN; YOGHURT;

ABDOMINAL TENDERNESS; ABSENCE OF SIDE EFFECTS; AGE; ANTIBODY PRODUCTION; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BIOLOGICAL THERAPY; BLOOD CELL COUNT; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DISINFECTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; ENZYME IMMUNOASSAY; FECAL BIOTHERAPY; FECES ANALYSIS; FEVER; FLUID THERAPY; HAND WASHING; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LENGTH OF STAY; LIVER CIRRHOSIS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PATHOGENESIS; PERMEABILITY BARRIER; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PROTEIN SECRETION; RADIATION EXPOSURE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; SIGMOIDOSCOPY; STREPTOCOCCUS THERMOPHILUS; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; PROBIOTICS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 84867949871     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.08.002     Document Type: Review

References (51)

1. McFarland L.V. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008, 3(5):563-578.
2. Doron S.I., Hibberd P.L., Gorbach S.L. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol 2008, 42(Suppl 2):S58-S63.
3. Young V.B., Schmidt T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004, 42(3):1203-1206.
4. Surawicz C.M. Role of probiotics in antibiotic-associated diarrhea, clostridium difficile associated diarrhea and recurrent clostridium difficile-associated diarrhea. J Clin Gastroenterol 2008, 42(Suppl 2):S64-S70.
5. Saavedra J.M. Use of probiotics in pediatrics: rationale, mechanisms of action, and practical aspects. Nutr Clin Pract 2007, 22:351-365.
6. Gorbach S.L. The discovery of lactobacillus GG. Nutr Today 1996, 31:25-45.
7. McFarland L.V., Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 1993, 6:157-171.
8. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. BMJ 2007, 335:80.
9. Gao X.W., Mubasher M., Fang C.Y., et al. Dose-response efficacy of a proprietary probiotic formula of lactobacillus acidophilus CL1285 and lactobacillus casei LBC8oR for antibiotic-associated diarrhea and clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010, 105:1636-1641.
10. Beausoleil M., Fortier N., Guenette S., et al. Effect of a fermented milk combining lactobacillus acidophilus CL1285 and lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 2007, 21(11):732-736.
11. Szajewska H., Ruszczynski M., Radzkowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006, 149:367-372.
12. Johnston B.C., Goldenberg J.Z., Vandvik P.O., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011, (11). CD004827. 10.1002/14651858.CD004827p.pub3.
13. D'Souza A.I., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic-associated diarrhea: meta-analysis. BMJ 2002, 324:1-6.
14. Cremonini F., Di Caro S., Nista E.C., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002, 16:1461-1467.
15. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
16. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in Adult Patients. World J Gastroenterol 2010, 16:2202-2222.
17. Duman D.G., Bor S., Qzutemiz O., et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005, 17:1357-1361.
18. Cindoruk M., Erkan G., Karakan T., et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007, 12:309-316.
19. Cremonini F., DiCaro S., Dovino M., et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002, 97:2744-2749.
20. Videlock E.J., Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhea. Aliment Pharmacol Ther 2012, 10.1111/j.1365-2036.2012.05104.x.
21. Bartlett J.G. Antibiotic-associated diarrhea. N Engl J Med 2002, 346(5):334-338.
22. Dethlefsen L., Huse S., Sogin M.L., et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008, 6(11):e280. 10.1371/journal.pbio.0060280.
23. Caetano L., Antunes M., Han J., et al. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother 2011, 55(4):1494-1503. 10.1128/AAC.01664-10.
24. Bartlett J.G. Narrative review: the new epidemic of clostridium difficile-associated enteric disease. Ann Intern Med 2006, 145:758-764.
25. Loo V.G., Poirier L., Miller M.A., et al. A predominant clonal multi-institutional outbreak of clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
26. McDonald L.C., Killfore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of clostridium difficile. N Engl J Med 2005, 353:2433-2441.
27. Riggs M.M., Sethi A.K., Zabarsky T.F., et al. Asymptomatic arriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45:992.
28. Cohen S.H., Gerding K.N., Johnson S., et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious Diseases Society of America (DSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
29. Sallhamer E.A., Carson K., Chang Y., et al. Fulminant Clostridium difficile Colitis. Arch Surg 2009, 144(5):433-439.
30. Nelson R.L., Kelsey P., Leeman H., et al. Antibiotic treatment in clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011, (9). CD004610. 10.1002/14651858.CD004610pub4.
31. Wenisch C., Parschalk B., Hasenhundl M., et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of clostridium difficile-associated diarrhea. Clin Infect Dis 1996, 22:813-818.
32. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for clostridium difficile infection. N Engl J Med 2011, 364(5):422-431.
33. Louie T.J., Peppe J., Watt C.K., et al. Tolevamer, a novel nonantibiotic polymer compared with vancomycin in the treatment of mild to moderately severe Clostridium dificile associated diarrhea. Clin Infect Dis 2006, 43:411-420.
34. Kelly C.P., LaMont J.T. Clostridium difficile - more difficult than ever. N Engl J Med 2008, 359:1932-1940.
35. Persky S.E., Brandt L. Treatment of recurrent clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000, 95:3283-3285.
36. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
37. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
38. Leung D.Y., Kelly C.P., Boguniewicz M., et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991, 118:633-637.
39. Sougioultzis S., Kyne L., Drudy D., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005, 128:764-770.
40. Aas J., Gessert C.E., Bakken J.S. Recurrent clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
41. Oughton M.T., Loo V.G., Dendukuri N., et al. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of clostridium difficile. Infect Control Hosp Epidemiol 2009, 30:939-944.
42. Stevens V., Dumyata G., Fine L.S., et al. Cumulative antibiotic exposures over time and the risk of clostridium difficile infection. Clin Infect Dis 2011, 53:42.
43. Valiquette L., Cossette B., Garant L.P., et al. Impact of a reduction in the use of high risk antibiotics in the course of an epidemic of clostridium difficile-associated disease caused by the hyper virulent NAP1/027 strain. Clin Infect Dis 2007, 45(Suppl 2):S112-S121.
44. Plummer S., Weaver M.A., Harris J.C., et al. Clostridium difficile pilot study: effects of probiotic supplementation in the incidence of C. difficile diarrhea. Int Microbiol 2004, 7:59-62.
45. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31:1012-1017.
46. Boyle R.J., Robins-Browne R.M., Tank Mimi L.K. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264.
47. Pakyz A., Carroll N.V., Harpe S.E., et al. Economic impact of Clostridium difficile infection in a multihospital cohort of academic health centers. Pharmacotherapy 2011, 31(6):546-551.
48. McGlone S.M., Bailey R.R., Zimmer S.M., et al. The economic burden of clostridium difficile. Clin Microbiol Infect 2012, 18(3):282-289.
49. Musa S., Thomson S., Cowan M., et al. Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol 2010, 45(3):261-272.
50. Kelsen J.R., Kim J., Latta D., et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17(1):50-55.
51. Hempel S., Newberry S.J., Maher A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea. JAMA 2012, 307(18):1959-1969.